RxDoctor Payments Data

Russell Palmer, MD

Internal Medicine · Carmel, INNPI 1427072263

Payments from drug & device makers

$2,834in general payments, 2019–2025

Across 168 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$677
  • Novo Nordisk$426
  • Amgen$264
  • Lilly USA, LLC$254
  • AstraZeneca$208
  • GSK$140
  • plus $865 from 18 others

What the payments were for

  • Food & beverage$2,834100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,834 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$100,288
Medicare patients
304
Services billed
1,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide83$92,982
JardianceEmpagliflozin61$69,174
EliquisApixaban69$46,197
OzempicSemaglutide45$38,164
RybelsusSemaglutide28$33,939
Synjardy XrEmpagliflozin/Metformin Hcl33$24,588
Soliqua 100-33Insulin Glargine/Lixisenatide19$23,823
XareltoRivaroxaban21$22,825
LinzessLinaclotide13$11,994
TrintellixVortioxetine Hydrobromide12$8,882
AbrysvoRsv Vacc, Pref A And Pref B/Pf27$8,491
Tresiba Flextouch U-100Insulin Degludec11$7,316
Incruse ElliptaUmeclidinium Bromide16$5,750
Atorvastatin Calcium521$4,555
Testosterone13$3,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$60$93,76294 claims
Lilly USA, LLCMounjaro$254$92,98283 claims
Novo NordiskOzempic, Rybelsus$426$72,10373 claims
PfizerEliquis, Abrysvo$120$54,68896 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$73$23,82319 claims
AbbVieLinzess, Synthroid$677$14,71440 claims
GSKIncruse Ellipta, Shingrix$140$9,02931 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$64$8,88212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →